This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Best-Performing ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
Time for Healthcare ETFs?
by Sanghamitra Saha
Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.
Will 2023 be the Year of Cathie Wood ETFs?
by Sanghamitra Saha
Cathie Wood, famous for the success of Ark Investment¿¿¿s winning products, had faced a miserable fate in 2022. Will her ETFs see success in 2023?
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Pharma & Biotech ETFs at One-Month High: Here's Why
by Sanghamitra Saha
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Is ARK's Stellar Run Over? 5 ETF Themes to Follow Cathie Wood
by Sanghamitra Saha
Though Cathie Wood's Ark Investment¿¿¿s star products underperformed in 2021 and may continue to lag the broader market in 2022, Wood's fans may follow these ETF strategies to capitalize on her vision.
Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan
by Sanghamitra Saha
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
How Are Genomics ETFs Responding to Q2 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
4 ETF Areas Surged Last Week
by Sanghamitra Saha
These four ETF areas were winners last week.
Top-Performing Biotech ETFs of Last Week
by Sweta Killa
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
by Sweta Jaiswal, FRM
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
ETFs in Focus on Bayer's Bet on Gene Therapy
by Sweta Killa
Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion.
Healthcare ETFs: Winners & Losers in the Light of U.S. Election
by Sanghamitra Saha
The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.
Why You Should Invest in Genomics ETFs
by Neena Mishra
Genomics ETFs have surged of late; here's why
Top Sector ETFs From Wall Street's Best Week in 3 Months
by Sanghamitra Saha
Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
by Sweta Jaiswal, FRM
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
Buy the Dip With These ETFs Under $20
by Sweta Killa
The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.
ETFs Under $20 From 5 Hottest Zones
by Sweta Killa
Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Genomics ETF (GNOM) Hits New 52-Week High
by Sanghamitra Saha
The ETF GNOM hit a 52-week high on May 22. Can it rally further?